ANDA 207457, held by Aurobindo Pharma Ltd. Naproxen Sodium; Sumatriptan Succinate.
As of Nov 16, 2026, ANDA 207457 (Sumatriptan And Naproxen Sodium), held by Aurobindo Pharma Ltd, was first approved by FDA on Feb 15, 2018, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 15, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sumatriptan And Naproxen Sodium500MG;EQ 85MG BASE · tablet;oral | Naproxen Sodium; Sumatriptan Succinate | Rx |
| Jun 24, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 15, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters